Browsing Tag
Bristol Myers Squibb
58 posts
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
What Sutro Biopharma’s restructuring says about biotech layoffs and investor sentiment in 2025
Sutro Biopharma (NASDAQ: STRO) slashes jobs and narrows its pipeline to extend cash runway into 2027. What does this restructuring mean for investors?
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.